IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases. We show 19 historical shares outstanding datapoints in our coverage of ISEE's shares outstanding history.
Understanding the changing numbers of ISEE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ISEE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ISEE by allowing them to research ISEE shares outstanding history
as well as any other stock in our coverage universe. |
Free ISEE Email Alerts:
Video: Shares Outstanding Importance
